Timber Creek Capital Management LLC Increases Stake in AstraZeneca PLC (NASDAQ:AZN)

Timber Creek Capital Management LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 63,227 shares of the company’s stock after purchasing an additional 453 shares during the quarter. AstraZeneca accounts for about 1.4% of Timber Creek Capital Management LLC’s holdings, making the stock its 29th biggest holding. Timber Creek Capital Management LLC’s holdings in AstraZeneca were worth $4,926,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in AZN. CANADA LIFE ASSURANCE Co boosted its position in AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock valued at $34,000 after buying an additional 146 shares during the period. Tidal Investments LLC purchased a new stake in AstraZeneca during the 1st quarter valued at $327,000. Cetera Investment Advisers boosted its position in AstraZeneca by 249.0% during the 1st quarter. Cetera Investment Advisers now owns 207,497 shares of the company’s stock valued at $14,058,000 after buying an additional 148,042 shares during the period. Cetera Advisors LLC boosted its position in AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock valued at $6,657,000 after buying an additional 54,488 shares during the period. Finally, Boston Partners bought a new position in AstraZeneca in the 1st quarter worth $309,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

AZN has been the subject of several research reports. TD Cowen upped their price objective on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $89.75.

AstraZeneca Stock Up 0.6 %

Shares of AstraZeneca stock opened at $67.62 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a 50-day moving average of $72.27 and a 200 day moving average of $77.44. The firm has a market cap of $209.66 billion, a price-to-earnings ratio of 32.35, a PEG ratio of 1.24 and a beta of 0.47. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the business earned $0.87 EPS. As a group, sell-side analysts anticipate that AstraZeneca PLC will post 4.1 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.